Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
A Japanese health ministry panel on October 27 finalized the designation of 762 APIs as “supply-ensured medicines,” currently known as “stable supply medicines.” The list — expanded from the initial 759 proposed APIs following a public comment process — will…
To read the full story
Related Article
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- Japan to Expand List of “Stable Supply Medicines” to 759 APIs, Adding Vaccines and Blood Products
August 28, 2025
- MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
August 18, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
March 30, 2021
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
REGULATORY
- Japan to Add VEXAS Syndrome, Mooren's Ulcer to Intractable Disease List
September 3, 2026
- MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
- MHLW Seeks 13.9 Billion Yen to Boost Domestic Biosimilar Production
September 2, 2026
- Health Minister Mum on Legislation for Chuikyo Reform
September 2, 2026
- Astellas, Kyowa Kirin 1st Japan Pharmas to Cut US MFN Deals
September 1, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…